Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension study of pasireotide versus Sandostatin in acromegaly
2004-002849-12Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jul 2005
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pasireotide LAR in acromegaly (4 arms), sponsored by Novartis. Primary endpoints: Long-term safety of pasireotide and Long-term efficacy of pasireotide. Started Jul 2005; status: terminated.
02
Drugs
pasireotide LAR
03
Conditions
acromegaly
Beyond the preview
Go deeper on 2004-002849-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002849-12.